Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (15)

COST-Bl Working Party on Population Approaches: L.Aarons(1), L.P.Balant(2), F.Mentre(3), P.L.Morselli(4), M.Rowland(1), J.-L.Steimer(5), and S.Vozeh(6)

Population Approaches in Drug Development: Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software

Carl Peck, Tom Ludden

Pitfalls in Retrospective Analysis in Search of Concentration-Effect Relationships

Mats O. Karlsson(1,3), Stuart L. Beal(2) and Lewis B. Sheiner(1,2)

Three New Residual Error Models For Population PK/PD Analyses

J.R. Wade, PhD(1,2), S.L. Beal PhD(2) and N.C. Sambol, PharmD(2)

Interaction between structural, statistical and covariate models in population pharmacokinetic analysis

Jaap W Mandema(1), Davide Verotta(2), and Lewis B Sheiner(2,3)

Diagnostics For Nonlinear Mixed Effects Models

Y. Merlé and F. Mentré

Comparison of Bayesian Optimal Designs with Respect to Variations of the Population Characteristics. For a Pharmacokinetic and a Pharmacodynamic Model

Constantin Efthymiopoulos, PhD, Valérie Cosson, Pharm D, Alan Bye, PhD

The Use of NONMEM in Interspecies Allometric Scaling

Alan V. Boddy, Michael Cole, Peng Bin, Andrew D.J. Pearson and David R. Newell

A limited sampling model with Bayesian estimation to determine carboplatin pharmacokinetics in paediatrics

E Chatelut(1,2), V Brunner(1), C Chevreau(1), A Pujol(1), H Roché(1), V Paschel(1), G Houin(2), R Bugat(1,2), P Canal(1)

Carboplatin Population Pharmacokinetics

Dr Alan Bye, Head of Clinical Pharmacokinetics Department

René Bruno, N. Vivier, J.C. Vergniol, G. Montay and L.B. Sheiner(1)

A Validation For A Population Pharmacokinetic Model For Docetaxel

Andrew P. Grieve

Combining Studies : Opportunities And Pitfalls

Jean-Louis Steimer, Marie-Eve Ebelin

Implementation of pharmacometric approaches into clinical drug development ? A prospective view

Lewis B. Sheiner, MD

The Future Place Of Modeling In Drug Development

Jon Wakefield

Review of methods